Effects of oral vasopressin on attention control using eye-tracking
The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study
This study is testing if taking a medication called vasopressin can help healthy people better focus on social and emotional cues compared to a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | University of Electronic Science and Technology of China Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06329037 on ClinicalTrials.gov |
What this trial studies
This study investigates how orally administered vasopressin affects attentional control towards socio-emotional stimuli in healthy individuals. Participants will take either vasopressin or a placebo and then perform a saccade/anti-saccade eye-tracking task that includes social and non-social stimuli. The study employs a double-blind, placebo-controlled design to ensure unbiased results. The aim is to validate previous findings regarding the role of vasopressin in socio-emotional processes.
Who should consider this trial
Good fit: Ideal candidates are healthy individuals who can provide informed consent and have normal or corrected vision.
Not a fit: Patients with a history of neuropsychiatric, cardiac, hepatic, or renal diseases, as well as those with certain hormonal imbalances or hypertension, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of attentional control mechanisms and the role of vasopressin in socio-emotional processing.
How similar studies have performed: Previous studies using intranasal vasopressin have shown effects on attentional control, suggesting potential success for this oral administration approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent. Normal or corrected-normal version Exclusion Criteria: * History of neuropsychiatric diseases. * History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness. * History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction. * History of renal diseases, including renal stones or renal failure. * History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus * Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food. * Infections such as COVID-19 or influenza, or unexplained fever. * Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg). * History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes. * Blood donation (≤ 1 month prior to administration). * Take oral contraceptives or receive hormonal medications in the three months prior to the experiment. * Pregnant or breastfeeding.
Where this trial is running
Chengdu, Sichuan
- University of Electronic Science and Technology of China — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Benjamin Becker, Dr — University of Electronic Science and Technology of China
- Study coordinator: Weihua Zhao, Dr
- Email: zarazhao.uestc@outlook.com
- Phone: 86-28-61830811
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.